ECCO 13 - Sunitinib prolongs survival in GIST patients after imatinib mesylate failure

November 03, 2005

Paris, France, Thursday 3 November 2005 - Updated results from a Phase III trial presented at the 13th European Cancer Conference (ECCO) show that sunitinib (SU11248) prolongs both progression-free and overall survival in patients with progressive metastatic and/or unresectable GIST whose disease has failed to respond to the standard therapy - imatinib mesylate.

This study was a double-blind, placebo-controlled, international, multicentre, Phase III trial involving 312 patients with GIST whose cancer had progressed despite previous treatment with imatinib mesylate. Failure of imatinib mesylate therapy was either the result of resistance or intolerance. Sunitinib treatment was in a repeated 6-week cycle consisting of a 50 mg capsule once daily for 4 weeks, followed by a 2-week break.

Results from the first planned interim analysis of this trial, disclosed at ECCO 13, demonstrate a 4-fold increase in the average time to progression (TTP) with sunitinib treatment, as compared to placebo. The estimated median TTP was 6.3 months with sunitinib, versus 1.5 months for placebo. Overall survival (OS) has also been estimated to be significantly greater with sunitinib therapy, although the average OS survival point has not yet been reached in either the sunitinib or placebo treatment arm.

Overall, treatment with sunitinib was well tolerated with fatigue, diarrhoea, nausea, sore mouth and skin discolouration proving to be the most common non-haematological side effects. Adverse events were generally mild to moderate and no severe effects (grade 4) were noted during the course of the study.

Dr George Demetri from the Dana-Farber Cancer Institute and Harvard Medical School, USA summarised: "These results from our global collaborative team provide important confirmatory evidence that documents the significant efficacy and acceptable tolerability of sunitinib (SU11248) in patients with metastatic GIST whose disease was resistant to imatinib, or those who experienced unacceptable side effects from imatinib. Before sunitinib, there was no therapy of proven value for such patients, and this trial shows that sunitinib has documented benefits"

Sunitinib is a mulitargeted drug which inhibits a number of important tyrosine kinase enzymes to exert antiangiogenic and antitumour effects.

According to Dr Demetri the study will have a considerable impact on future treatments, "The development of sunitinib (SU11248) has proceeded exceptionally fast, with the first GIST patient having started the drug in 2002, and now completion of a global Phase III clinical trial to confirm the benefits in 2005. This timeline represents the future of truly effective, targeted therapies which home in on the molecular causes of cancer. Once these targets are neutralised by effective new drugs, the benefits in terms of treating cancers such as GIST can be documented. The results of this trial will change therapy for GIST patients worldwide by introducing a new and effective agent into the physicians' therapeutic armamentarium. We have much to learn about the patients who benefit the most from SU11248 therapy, and we are already working to expand and enhance the ability to manage GIST patients using this new agent alone or in combination therapies."

He continued to comment, "The trial that we have performed shows that patients will benefit by control of GIST even in the absence of tumour shrinkage. SU11248 can stabilise the disease and prevent worsening, which translates into disease control and longer survival for GIST patients whose disease is resistant to imatinib."

Gastrointestinal stromal tumours (GISTs) are an extremely rare type of soft tissue sarcoma that arise from cells of the stroma, the connective tissue that supports the digestive organs. About 60% of GISTs occur in the stomach, but they can appear anywhere along the length of the digestive system from the oesophagus to the anus.

About Gastrointestinal Stromal tumours (GIST)

Gastrointestinal stromal tumours (GISTs) belong to a group of cancers called soft tissue sarcomas. They are cancers that develop in the supporting or connective tissues of the body i.e. muscle, fat, nerves, blood vessels, bone and cartilage. GISTs are a rare type of soft tissue sarcoma and 60% occur in the stomach, but they can occur anywhere along the length of the digestive system from the oesophagus to the anus.

There are over 170,000 cases of stomach cancer in Europe each year and it is the cause of just under 140,000 deaths annually.1 GISTs usually affect middle-aged and older patients with a median age of 50 to 60 years. They are rare before the age of 40 and very rare in children.3

The exact causes of GIST are unknown but research indicates that most GIST cells have an enzyme disorder relating to the tyrosine kinase enzyme. This enzyme is responsible for sending signals inside cells to stimulate growth and cell division. It may be associated with a family history but usually occurs spontaneously in the population.1

As with all cancers, GISTs are staged and graded before treatment is commenced. Stage 1 is considered localised and Stage 4 is when the tumours have become invasive and spread to other parts of the body.

Until relatively recently, treatment was mainly surgery and chemotherapy which had limited success. Newer therapies such as imatinib mesylate and sunitinib which interfere with growth factors and signal transduction proteins (tyrosine kinase inhibitors) are offering patients alternatives and prolonging patient survival.
2 Boyle, P. Cancer incidence and mortality in Europe, 2004. International Agency for Research on Cancer. 2004, p.483
3 Chandu de Silva, M V & Reid, R. Gastrointestinal stromal tumours (GIST), February 2005, Orphanet encyclopedia

For further information please contact:
Tonic Life Communications:
Stéphanie Makin: + 44 7769 673 973 or e-mail or
Kirsten Mason: + 44 7796 955 353 or e-mail

Press room:
Telephone: + 33 (0)1 40 68 27 45/ + 33 (0)1 40 68 27 46
Telefax: + 33 (01) 40 68 27 49/ + 33 (01) 40 68 27 52

For any enquiries after Thursday 3rd November 2005, please contact:
Stéphanie Makin: + 44 (0)20 7798 9905 or e-mail or
Kirsten Mason: + 44 (0)20 7798 9911 or e-mail

Abstract: 716
GI - GIST tumours
Sunitinib malate (SU11248) prolongs progression-free and overall survival for GIST patients after failure of imatinib mesylate therapy: update of a phase III trial
G. Demetri1, A. van Oosterom2, C. Garrett3, M. Blackstein4, M. Shah5, J. Verweij6, G. McArthur7, I. Judson8, C. Baum9, P. Casali10
1Dana-Farber Cancer Institute, Boston, USA
2UZ Gasthuisberg, Leuven, Belgium
3H. Lee Moffitt Cancer Center, Tampa, USA
4Mount Sinai Hospital and the University of Toronto, Toronto, Canada
5Ohio State University, Columbus, USA
6Erasmus Medical Center, Rotterdam, The Netherlands
7Peter MacCallum Cancer Center, East Melbourne, Australia
8Royal Marsden Hospital, Sutton, United Kingdom
9Pfizer Inc., La Jolla, USA
10Istituto Nazionale Tumouri, Milan, Italy

Sunitinib (SU) is an oral multitargeted tyrosine kinase inhibitor of VEGFR, PDGFR, KIT, RET and FLT-3 with antiangiogenic and antitumour activities. This study assessed the efficacy and safety of SU in patients (pts) with progressive metastatic and/or unresectable GIST following failure of prior imatinib mesylate (IM) therapy due to resistance or intolerance.

Patients and methods:
In this double-blind, placebo-controlled, international, multicentre, phase III trial, 312 pts with documented progression of GIST despite previous IM therapy were randomised 2:1 to receive SU (n=207) or placebo (n=105). SU was administered as 50 mg capsules once daily for 4 weeks, followed by a 2-week break, in repetitive 6 week cycles. Pts in the placebo arm were offered the opportunity to receive open-label SU if RECIST-defined disease progression occurred. The primary study endpoint was time to progression (TTP). Secondary endpoints included overall survival (OS), response rates, time to tumour response, duration of response, functional status and clinical benefit-related parameters (McGill Pain Questionnaire, investigator-rated changes in severity of signs and symptoms and other pt-reported outcomes) as well as tolerability and safety assessments.

SU therapy resulted in a >4-fold increase in median TTP compared with placebo (HR 0.335, P<0.00001) at the first planned interim analysis for efficacy. Estimated median TTP was 6.3 months with SU vs. 1.5 months with placebo. SU improved the TTP in pts with either primary or secondary resistance to IM. SU was also associated with significantly greater estimated OS (HR 0.491; P=0.00674). The median OS has not yet been reached in either treatment arm. A total of 59 pts in the placebo group crossed over following disease progression to receive SU, with 10% subsequently exhibiting a partial response as assessed by investigators. SU therapy was well tolerated overall, with the most common non-haematologic adverse effects (AEs) being fatigue, diarrhoea, nausea, sore mouth and skin discolouration. AEs were generally mild to moderate (grade 1 or 2), and there were no grade 4 events during the study.

SU was associated with significant efficacy and acceptable tolerability in this large-scale international phase III trial of GIST pts resistant to or intolerant of IM therapy.

ECCO-the European CanCer Organisation

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to